Here is the complete patent application following the provided outline and based on the research paper:

# DESCRIPTION  

## BACKGROUND OF THE INVENTION  

The field of the invention relates generally to biometric monitoring devices and methods for cardiovascular health assessment. More particularly, the invention pertains to a system and method for continuous cardiovascular monitoring using infrasonic hemodynography (IH) technology embedded within in-ear headphones.  

Current wearable digital health technologies (DHTs) for cardiac monitoring face significant limitations in accuracy, power consumption, and continuous monitoring capabilities. While consumer wearables such as smartwatches and activity trackers can measure heart rate and other cardiovascular parameters, they typically exhibit error rates up to 10% in heart rate measurements alone. These devices are further constrained by limitations in memory, data storage, and processing power, which restrict their ability to provide precise, continuous beat-to-beat measurements required for comprehensive cardiovascular assessment.  

Existing medical-grade monitoring systems, such as electrocardiography (ECG), provide accurate measurements but are cumbersome, requiring multiple electrodes attached to the body, making them unsuitable for continuous, long-term monitoring in everyday settings. There remains an unmet need for a convenient, wearable device that can bridge the gap between consumer wearables and medical-grade monitoring systems by providing continuous, accurate cardiovascular measurements without sacrificing user comfort or mobility.  

## SUMMARY OF THE INVENTION  

The present invention provides a system and method for continuous cardiovascular monitoring using in-ear infrasonic hemodynography (IH) technology. The invention comprises earbuds equipped with specialized acoustic sensors capable of detecting infrasonic biosignals (0-20 Hz) associated with cardiovascular activity within the ear canal. The system utilizes the natural acoustic properties of the occluded ear canal to amplify these biosignals, enabling precise measurement of cardiac parameters such as interbeat intervals (IBI), heart rate (HR), and heart rate variability (HRV).  

Key aspects of the invention include:  

1. An in-ear headphone system comprising at least one earbud containing an infrasonic sensor configured to detect pressure fluctuations in the ear canal associated with cardiovascular activity, wherein the earbud creates an acoustic seal with the ear canal to amplify infrasonic biosignals.  

2. A signal processing pipeline that filters environmental noise and motion artifacts while extracting cardiac features from the infrasonic signals, enabling accurate beat-to-beat measurement comparable to medical-grade ECG.  

3. A machine learning algorithm trained to classify cardiac rhythms, including detection of atrial fibrillation (AF), based on analysis of interbeat interval patterns derived from the IH signals.  

4. A wireless communication system that enables continuous data streaming to cloud-based processing infrastructure for real-time analysis and long-term monitoring.  

The invention demonstrates correlation coefficients of 0.988 for IBI and 0.994 for HR when compared to simultaneous ECG measurements, with mean differences of 0.05 ms and 0.03 bpm respectively. The system maintains this accuracy even during physiological maneuvers that induce large IBI variations, such as resonant breathing exercises and Valsalva maneuvers. Furthermore, the IH technology shows equivalent performance to ECG in detecting atrial fibrillation, with sensitivity and specificity both exceeding 0.99 in clinical testing.  

## DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS  

The preferred embodiments of the invention will now be described with reference to the accompanying drawings, which illustrate specific implementations of the IH technology. These embodiments are provided to enable those skilled in the art to practice the invention, but are not intended to limit the scope of the claims.  

**In-Ear Headphone System Architecture**  

The IH system comprises a pair of earbuds connected to a controller unit. Each earbud contains:  
- An infrasonic sensor (typically a high-sensitivity microphone) positioned to detect pressure fluctuations in the ear canal  
- A speaker for audio output  
- An ear tip designed to create an acoustic seal with the ear canal  

The controller unit contains:  
- A processor for initial signal processing  
- Wireless communication circuitry (preferably Bluetooth Low Energy)  
- Power management components  
- Optional wired connection ports for clinical applications  

In the preferred embodiment, the infrasonic sensors are passive components that do not require active signal transmission, minimizing power consumption. The system is designed to operate continuously for extended periods while streaming data to a paired mobile device or directly to cloud infrastructure.  

**Acoustic Signal Processing**  

The invention leverages the acoustic properties of the sealed ear canal to amplify cardiovascular biosignals. When the earbud forms an airtight seal with the ear canal, the effective acoustic volume is reduced, increasing the acoustic impedance according to the equation:  

Za ≈ (ρc²)/(jωV)  

Where:  
- Za = acoustic impedance  
- ρ = density of air (1.21 kg/m³)  
- c = speed of sound in air (343 m/s)  
- ω = angular frequency  
- V = volume of the ear canal cavity  

This impedance increase results in amplification of infrasonic biosignals by up to 40 dB compared to an open ear canal, bringing the signals into measurable range for commercial microphones. The sealed environment also blocks external noise, further improving signal quality.  

**Signal Processing Pipeline**  

The invention employs a multi-stage signal processing pipeline:  

1. **Level 1 - Raw Signal Acquisition**:  
   Continuous data streams are collected from left and right earbuds at a sampling rate of 1000 Hz. The raw signals may contain artifacts from motion, environmental noise, or audio playback.  

2. **Level 2 - Calibration and Filtering**:  
   The system applies corrections for audio playback through the earbuds and filters signals above 20 Hz to isolate the infrasonic range. Adaptive noise cancellation techniques remove residual environmental noise.  

3. **Level 3 - Quality Assessment**:  
   A neural network classifier analyzes signal segments to identify and reject poor-quality data caused by motion artifacts or improper earbud fit. The classifier uses >20 time-domain features including statistical parameters and morphological characteristics of the waveform.  

4. **Level 4 - Feature Extraction**:  
   Cardiac events are identified using adaptive threshold peak detection. Additional waveform features corresponding to physiological events (e.g., aortic valve opening/closing) are extracted for comprehensive cardiovascular assessment.  

5. **Level 5 - Vital Sign Calculation**:  
   Interbeat intervals are computed from successive peak detections. Data from both earbuds are merged, favoring the channel with higher quality scores. Heart rate, heart rate variability, and respiratory rate are derived from the processed signal.  

**Cardiac Rhythm Classification**  

The invention includes a machine learning algorithm for detecting cardiac arrhythmias, particularly atrial fibrillation. In the preferred embodiment, a random forest classifier is trained on external ECG datasets containing both sinus rhythm and AF samples. The algorithm analyzes 17 features derived from 30-second segments of interbeat interval data, including:  

- Poincaré plot dispersion metrics  
- pNN50 (percentage of successive IBIs differing by >50 ms)  
- Time-domain and frequency-domain measures of HRV  
- Statistical properties of the IBI sequence  

The trained model achieves sensitivity and specificity >0.99 for AF detection when applied to both ECG and IH data. This performance is maintained even with the fundamentally different waveform characteristics between IH and ECG signals.  

**Clinical Validation**  

The invention has been validated in two clinical studies:  

1. **Sinus Rhythm Study (n=25)**:  
   - Demonstrated correlation coefficients of 0.988 for IBI and 0.994 for HR compared to simultaneous ECG  
   - Maintained accuracy during breathing maneuvers inducing IBI variations up to 400 ms  
   - Showed equivalent performance during music playback and resonant breathing exercises  

2. **Atrial Fibrillation Study (n=15)**:  
   - Maintained high correlation (r=0.99) for IBI measurements in AF patients  
   - Demonstrated equivalent AF detection performance to ECG (sensitivity and specificity >0.99)  

The system's ability to track rapid physiological changes was validated through various breathing exercises:  

- Regular breathing (HRV 17-22 ms)  
- Resonant breathing with different inhale-to-exhale ratios (4:4, 4:6, 5:7)  
- Valsalva maneuver (IBI changes >400 ms)  

In all cases, paired t-tests showed no significant difference between IH and ECG measurements (p>0.05).  

**Implementation Variations**  

While the preferred embodiment uses wired earbuds connected to a controller for clinical validation, the invention encompasses several implementation variants:  

1. **Wireless Earbuds**:  
   - True wireless earbuds with onboard processing and wireless data transmission  
   - Incorporation of motion sensors for improved artifact rejection  

2. **Cloud-Based Processing**:  
   - Real-time data streaming to cloud infrastructure for continuous monitoring  
   - Server-side machine learning for arrhythmia detection  
   - Long-term data storage for trend analysis  

3. **Hybrid Medical/Consumer Devices**:  
   - Integration with active noise cancellation technology  
   - Combination with audio playback for consumer applications  
   - Medical-grade certification for clinical use  

The invention represents a significant advancement in wearable cardiovascular monitoring, combining the accuracy of medical devices with the convenience and wearability of consumer earbuds. Its ability to provide continuous, precise cardiac measurements in everyday settings enables new paradigms in preventive healthcare and remote patient monitoring.